McIntyre, Freedman & Flynn Investment Advisers’s iShares Biotechnology ETF IBB Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18M	Sell	11,488 -627	-5%	-$108K	1.31%	27
2026 Q1	$2.05M	Sell	12,115 -87	-0.7%	-$14.9K	1.16%	29
2025 Q4	$2.06M	Sell	12,202 -1,200	-9%	-$195K	1.29%	27
2025 Q3	$1.93M	Sell	13,402 -50	-0.4%	-$6.83K	1.16%	30
2025 Q2	$1.7M	Hold	13,452	–	–	1.2%	28
2025 Q1	$1.72M	Sell	13,452 -450	-3%	-$61K	1.27%	30
2024 Q4	$1.84M	Hold	13,902	–	–	1.37%	29
2024 Q3	$2.02M	Sell	13,902 -199	-1%	-$28.8K	1.44%	27
2024 Q2	$1.94M	Hold	14,101	–	–	1.4%	28
2024 Q1	$1.93M	Sell	14,101 -300	-2%	-$41K	1.41%	28
2023 Q4	$1.96M	Sell	14,401 -50	-0.3%	-$6.1K	1.57%	27
2023 Q3	$1.77M	Sell	14,451 -75	-0.5%	-$9.54K	1.49%	27
2023 Q2	$1.84M	Hold	14,526	–	–	1.58%	29
2023 Q1	$1.88M	Sell	14,526 -1,800	-11%	-$236K	1.59%	28
2022 Q4	$2.14M	Buy	+16,326	New	+$2.11M	1.77%	27

Other funds holding IBB

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

McIntyre, Freedman & Flynn Investment Advisers's IBB Position: Q2 2026 in Review

McIntyre, Freedman & Flynn Investment Advisers reduced its iShares Biotechnology ETF (IBB) stake by 5.2% in Q2 2026, selling an estimated $108K and leaving 11,488 shares worth $2.18M. The position accounts for 1.31% of the portfolio, ranked #27.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in IBB in Q4 2022 and has held it in 15 quarters since. 758 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

McIntyre, Freedman & Flynn Investment Advisers held 11,488 shares of iShares Biotechnology ETF worth $2.18M as of Q2 2026.
McIntyre, Freedman & Flynn Investment Advisers sold 627 iShares Biotechnology ETF shares in Q2 2026, an estimated $108K.
iShares Biotechnology ETF made up 1.31% of McIntyre, Freedman & Flynn Investment Advisers's portfolio in Q2 2026, its #27 holding.
McIntyre, Freedman & Flynn Investment Advisers first reported a position in iShares Biotechnology ETF in Q4 2022 and has held it in 15 quarters since.
758 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.